

1 ***Akkermansia muciniphila* identified as key strain to alleviate gut**
2 **barrier injury through Wnt signaling pathway**

3 Xin Ma ^{a,b}, Meng Li ^{a,b}, Yuanyuan Zhang ^b, Tingting Xu ^b, Xinchen Zhou ^{a,b}, Mengqi Qian ^b,
4 Zhiren Yang ^{a,b}, Xinyan Han ^{a,b,*}

5 ^a Hainan Institute of Zhejiang University, Yongyou Industry Park, Yazhou Bay Sci-Tech City,
6 Sanya 572000, China

7 ^b Key Laboratory of Animal Nutrition and Feed Science in East China, Ministry of
8 Agriculture, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China

9 *Corresponding author

10 Xinyan Han

11 College of Animal Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058,

12 China

13 E-mail: xyhan@zju.edu.cn

14

15 Credit author statement

16 XH and XM: Designed the experiments; XM and TX: Performed the experiments; XZ
17 and MQ: Analyzed the data; XM and ML: Wrote the manuscript, which was edited by YZ, TX,
18 MQ, XZ, ZY and HX. All authors read and approved the final manuscript.

19

20 **ABSTRACT**

21 As the largest mucosal surface, the gut has built a physical, chemical, microbial and
22 immune barrier to protect the body against pathogen invasion. The disturbance of gut
23 microbiota aggravates pathogenic bacteria invasion and gut barrier injury. Fecal microbiota
24 transplantation (FMT) is a promising treatment for microbiome-related disorders, where
25 beneficial strain engraftment is a significant factor influencing FMT outcomes. The aim of
26 this research was to explore the effect of FMT on antibiotic-induced microbiome-disordered
27 (AIMD) model infected with enterotoxigenic *Escherichia coli* (ETEC). We used piglet, mouse
28 and intestinal organoid models to explore the protective effects and mechanisms of FMT on
29 ETEC infection. The results showed that FMT regulated gut microbiota and enhanced the
30 protection of AIMD piglets against ETEC K88 challenge, as demonstrated by reduced
31 intestinal pathogen colonization and alleviated gut barrier injury. *Akkermansia muciniphila* (*A.*
32 *muciniphila*) and *Bacteroides fragilis* (*B. fragilis*) were identified as two strains that may play
33 key roles in FMT. We further investigated the alleviatory effects of these two strains on ETEC
34 infection in AIMD mice model, which revealed that *A. muciniphila* and *B. fragilis* relieved
35 ETEC-induced intestinal inflammation by maintaining the proportion of Treg/Th17 cells and
36 epithelial damage by moderately activating the Wnt/ β -catenin signaling pathway, while the
37 effect of *A. muciniphila* was better than *B. fragilis*. We therefore identified whether *A.*
38 *muciniphila* protected against ETEC infection using basal-out and apical-out intestinal
39 organoid models. *A. muciniphila* did protect the intestinal stem cells and stimulate
40 proliferation and differentiation of intestinal epithelium, and the protective effects of *A.*
41 *muciniphila* was reversed by Wnt inhibitor. FMT alleviated ETEC-induced gut barrier injury
42 and intestinal inflammation in AIMD model. *A. muciniphila* was identified as key strain in
43 FMT to promote proliferation and differentiation of intestinal stem cells by mediating the
44 Wnt/ β -catenin signaling pathway.

45 **Keywords:** *Akkermansia muciniphila*; Wnt/ β -catenin signaling pathway; Apical-out intestinal
46 organoids; Gut barrier injury; Fecal microbiota transplantation.

47

48 **Introduction**

49 Growing evidence suggests that gut microbiota and its metabolites play important roles
50 in modulating host health (*Canfora et al., 2019; Ghosh et al., 2021; Zheng et al., 2021*). The
51 most drastic exposure that leads to intestinal microbiota dysbiosis is antibiotic treatment,
52 which kills commensal micro-organisms and inhibits these microbiota-mediated immune
53 defense (*Andremont et al., 2021; Buffie and Pamer, 2013*). The disturbance of intestinal
54 microbiota may lead to disruptions of gut barrier and increase the susceptibility of host to
55 pathogenic microbes (*Flint et al., 2012; Witkowski et al., 2020*). Several clinical studies have
56 demonstrated that early-life exposure to antibiotic leads to gut microbiota dysbiosis that can
57 impair host immune system maturation (*An et al., 2014; Nguyen et al., 2020*). Furthermore,
58 the negative impact of antibiotics on gut microbiota in early life may even last for long
59 periods throughout a lifetime, increasing the risk of gut diseases (*Francino, 2016*).
60 Enterotoxigenic *Escherichia coli* (ETEC) K88 infection is a common cause of diarrhea in
61 humans and animals (*Dubreuil, 2021*). When ETEC adheres to intestinal epithelial cells,
62 virulence factors interact with specific receptors to induce intestinal barrier injury and
63 intestinal inflammatory responses (*Yu et al., 2018*). Fecal microbiota transplantation (FMT) is
64 a therapeutic intervention for reconstructing gut microbiota in gastrointestinal inflammatory
65 diseases (*Borody et al., 2019; Colman and Rubin, 2014*). Since FMT has been successful in
66 treating *Clostridioides difficile* infection and maintaining gut barrier, emerging investigation
67 has been focused on other diseases (*Quraishi et al., 2017*). However, whether FMT could
68 remedy against ETEC K88 infection in antibiotic-induced gut microbiota-disordered (AIMD)
69 piglets is still unknown. Simultaneously, the underlying mechanism of FMT and the gut
70 microbes that confer its efficacy remain unclear.

71 Intestinal stem cell renewal is vital for the maintenance of gut barrier (*Beumer and*
72 *Clevers, 2021*). Mammalian intestinal epithelial cells are renewed approximately every 3-5
73 days with the migration of undifferentiated intestinal cells from the crypt to the top of the villi,
74 accompanied by the differentiation of different types of epithelial cells (*Luo et al., 2022*). The
75 proliferation and differentiation of intestinal epithelium driven by intestinal stem cells, mainly

76 crypt base columnar cells expressing R-Spondin receptor Lgr5, is a necessary process for
77 repairing intestinal barrier injury to prevent pathogen invasion (*Yan et al., 2017*). *Sato et al.*
78 (2009) successfully cultured isolated intestinal stem cells into three-dimensional intestinal
79 organoids with villous and crypt-like structural morphology for the first time. Intestinal
80 organoids contain various terminally differentiated cell types, including intestinal stem cell,
81 tuft cell, absorptive cell, enteroendocrine cell, goblet cell, and Paneth cell, which have more
82 advantages over single cell lines for *in vitro* study of intestinal regeneration (*Sprangers et al.,*
83 *2021*). Intestinal organoid is an ideal model for studying the interaction between intestinal
84 epithelium and microorganisms *in vitro*, which can eliminate the complexity of animal models
85 (*Yin et al., 2019*). In traditional basal-out intestinal organoid models, the intestinal epithelium
86 was in the interior of organoid spheroid, which restricted the interaction between intestinal
87 epithelium and gut microbiota. *Co et al. (2019)* first established the intestinal organoid model
88 with polarity reversal in human and mouse, which optimizes the shortcomings of
89 microinjection in terms of heterogeneous exposure concentrations and durations, as well as
90 destruction of organoid walls, and evaluated the infection effects of the invasive pathogens
91 with different polarity-specific patterns.

92 In the present study, we first investigated the effects of FMT on ETEC K88 infection in
93 AIMD neonatal piglets, then by using bacterial 16S rDNA sequencing analysis, we identified
94 *Akkermansia muciniphila* (*A. muciniphila*) as potential microbe to alleviate ETEC-induced
95 intestinal barrier injury. We further hypothesized that *A. muciniphila* could relieve intestinal
96 barrier injury and intestinal inflammation by modulating the proliferation and differentiation
97 of intestinal epithelium, and verified this hypothesis using *in vivo* mice experiments as well as
98 *in vitro* porcine intestinal organoid models. Collectively, our results may provide theoretical
99 basis that *A. muciniphila* is a promising method to repair intestinal barrier damage and a new
100 strategy for the precise application of *A. muciniphila* in livestock production.

101

102 **Materials and methods**

103 **Ethics statement**

104 All animal experiments were performed according to the guidelines of the Animal Care
105 Committee of Zhejiang University School of Medicine (permit number SYXK 2012-0178).
106 The animal care protocol was approved by the Local Committee of Animal Use following the
107 Guide for the Care and Use of Laboratory Animals (NIH publication 86-23 revised 1985).

108

109 **Preparation of fecal microbiota suspension and bacterial strains**

110 The fecal microbiota suspension was prepared according to our previous method (*Ma et*
111 *al., 2021*). In short, healthy adult Jinhua pigs that administrated medicinal feed additives or
112 drugs for more than 3 months were selected as fecal donors. The potential risks and infectious
113 pathogens in donor pigs were determined by serological and stool testing to ensure the safety
114 of the porcine FMT. Fresh fecal samples that collected from Jinhua pigs were transported in
115 AnaeroPack (Mitsubishi Gas Chemical, Japan) on ice to laboratory within 2 hours. The 50 g
116 fecal samples were homogenized in 250 mL sterile phosphate-buffered saline solution (PBS),
117 filtered through sterile stainless-steel strainer, and then centrifuged at 4000 rpm for 10 min.
118 The precipitate was resuspended in sterile PBS solution containing 10% sterile glycerol, and
119 the fecal microbiota suspension was stored at -80°C. All the above preparation was performed
120 in an anaerobic incubator (AW400SG anaerobic workstations; Electrotek, UK). All the
121 facilities and tools for the preparation of the fecal microbiota suspension were sterilized prior
122 to use. When processing the FMT, the fecal microbiota suspension was thawed in 37°C water
123 bath. ETEC K88 serotype O149:K91:K88ac was purchased from the China Institute of
124 Veterinary Drug Control (Beijing China), cultured in Luria-Bertani medium (Qingdao Hope
125 Bio-Technology Company, China), and incubated at 37°C in a shaker with 250 rpm overnight.
126 *A. muciniphila* ATCC BAA-835 and *Bacteroides fragilis* (*B. fragilis*) ATCC 25285 were
127 purchased from Guangdong Microbial Culture Collection Center (GDMCC, Guangzhou,
128 China). *A. muciniphila* was cultured in brain heart infusion media (OXOID, Thermo Fisher
129 Biochemicals Ltd., UK) supplemented with 0.1% mucin (Sigma-Aldrich, USA). *B. fragilis*
130 was cultured in trypticase soy broth (Qingdao Hope Bio-Technology Company, China)
131 supplemented with 5% defibrinated sheep blood (Qingdao Hope Bio-Technology Company,

132 China). These two anaerobic bacteria strains were incubated at 37°C in an anaerobic incubator
133 with 10% H₂, 10% CO₂, and 80% N₂ (AW400SG anaerobic workstations; Electrotek, UK).
134 The cultures were centrifuged for 10 min at a speed of 4000 rpm, and the pellets were then
135 resuspended in either aerobic or anaerobic PBS.

136

137 **Animals**

138 A total of 9 litters (9-11 piglets per litter) of Duroc × Landrace × Yorkshire ternary
139 hybrid neonatal piglets (aged 5 days) with identical birth dates and parities were obtained
140 from Anji Lvjiayuan Animal Husbandry Co. Ltd. (Zhejiang, China). Piglets were individually
141 housed in pens with appropriate environment of 24-26°C and 55-65% humidity. All newborn
142 piglets were fed with artificial milk substitutes, in which the nutrients reached the
143 requirements recommended by the National Research Council (NRC, 2012), and had *ad*
144 *libitum* access to water.

145 A total of 130 female C57BL/6 mice aged 5 weeks were obtained from Shanghai SLAC
146 Laboratory Animal, Co., Ltd. (SCXK (Zhejiang) 2017-0005; Shanghai, China). Mice were
147 housed in vinyl isolators in a room with 23 ± 1°C room temperature, 55-65% humidity and 12
148 h/12 h light/dark schedule. All mice had free access to water and food.

149

150 **Experimental design**

151 The piglets were randomly assigned to three groups (three litters per group): the control
152 group (Con group), the ETEC K88 + PBS group (EP group) and the ETEC K88 + FMT group
153 (EF group). The piglets in EP and EF groups were orally inoculated with 2 ml ampicillin (120
154 mg kg⁻¹) twice daily on day 1-3 of the experiment to disorder the intestinal resident
155 microbiota, then orally inoculated with ETEC K88 (1 × 10⁹ CFU ml⁻¹) suspended in 2 ml
156 sterile PBS once daily on day 4-6 of the experiment. After ETEC K88 infection, the piglets in
157 EF group received 1.5 ml fecal microbiota suspension once daily by oral gavage for 6 days,
158 while the piglets in EP group received the same volume of sterile PBS. Meanwhile, the piglets
159 in Con group were orally inoculated with the same volume of sterile PBS throughout the

160 experiment. The doses of ampicillin and fecal microbiota suspension were based on a
161 previous study by Ma et al. [18]. Experimental design of piglets is shown in Figure 1A. The
162 weight of each piglet was measured at both the beginning and the end of the experiment to
163 calculate the average daily gain (ADG), and diarrhea score (0, normal feces; 1, moist feces; 2,
164 mild diarrhea; 3, severe diarrhea) was recorded throughout the experiment. Six piglets (2
165 piglets per litter) were picked from each group to be slaughtered at the end of the experiment
166 (Day 13).

167 After acclimating for a week, mice were randomly assigned to four groups (n = 10 each):
168 the control group (C group), the ETEC K88 + PBS group (E group), the ETEC K88 + *A.*
169 *muciniphila* group (A group) and the ETEC K88 + *B. fragilis* group (B group). On day 1-3 of
170 the experiment, the mice in E, A and B groups were orally inoculated with 0.2 ml 15 mg ml⁻¹
171 ampicillin (Sigma-Aldrich, USA) twice daily to disorder the gut microbiota. On day 4-6 of the
172 experiment, the mice in E, A and B groups were infected with ETEC K88 (1×10^9 CFU)
173 suspended in 0.2 ml 0.1 M NaHCO₃ buffer (pH 9.0) by oral gavage once daily. Mice were
174 fasted for 12 h before infection. Meanwhile, the mice in C group were given the equal volume
175 of sterile PBS on day 1-6 of the experiment. On day 7-13 of the experiment, live *A.*
176 *muciniphila* (1×10^6 CFU) and live *B. fragilis* (1×10^8 CFU) suspended in 0.2 ml anaerobic
177 sterile PBS were administered intragastrically once daily to the mice in A group and B group
178 respectively, while mice in C and E groups received the same volume of anaerobic sterile PBS.
179 The design of mouse experiment is shown in Figure 1B. Mice were orally infused with 0.2 ml
180 40 mg ml⁻¹ 4 kDa fluorescein isothiocyanate-dextran (Sigma-Aldrich, USA) 4 hours before
181 sampling. At the end of the experiment (Day 14), six mice in each group were randomly
182 selected for ether anesthesia and neck dislocation.

183

184 **Culture and treatment of porcine intestinal organoid**

185 The cryovial of porcine intestinal organoid was kindly provided by Professor Li
186 Xiaoliang (Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang
187 University, Hangzhou, China). The frozen organoids were thawed in a 37°C-water bath for 2

188 min, and then added 1 ml of DMEM/F-12 (Gibco, USA) with 1% bovine serum albumin
189 (BSA, BioFroxx, Germany) solution. The contents of the cryovial were mixed and transferred
190 to the 15 ml conical tube containing 2 ml of DMEM/F-12 with 1% BSA solution, and then
191 centrifuged at $200 \times g$ for 5 min at 4° . The organoids were resuspended in equal volume of
192 complete IntestiCult™ Organoid Growth Medium (06010, StemCell™ Technologies, Canada)
193 and Matrigel Matrix (356231, Corning, USA). The 50 μ l of the 500-crypt suspension was
194 plated in the center of each well of the pre-warmed 24-well plate (3524, Corning, USA). The
195 plate was placed at 37° with 5% CO_2 for 10 min and then added 750 μ l complete
196 IntestiCult™ Organoid Growth Medium containing 100 $\mu\text{g ml}^{-1}$ penicillin/streptomycin
197 (Invitrogen, USA) to each well. The culture medium was fully exchanged three times per
198 week. For the treatment, the frozen organoids were passaged two times after thawing.

199 For generation of apical-out organoids, the procedure of reversing the polarity of
200 organoids was performed according to a previously published protocol by *Co et al. (2021)*.
201 Briefly, after growing in Matrigel Matrix with growth medium for 7 days, the Matrigel-
202 embedded organoids were gently dissolved with 500 μ l cold 5 mM ethylene diamine
203 tetraacetic acid (EDTA) in D-PBS and transferred to the 15 ml conical tube containing 10 ml
204 of cold 5 mM EDTA. The tubes were incubated on a rotating platform at 4° for 1 h, and then
205 centrifuged at $200 \times g$ for 3 min at 4° . The organoids were resuspended in complete
206 IntestiCult™ Organoid Growth Medium containing 100 $\mu\text{g ml}^{-1}$ penicillin/streptomycin and
207 transferred to ultra-low attachment 24-well plate (3473, Corning, USA). The suspended
208 organoids were cultured at 37° with 5% CO_2 for 3 days.

209 To induce intestinal damage, the culture medium of basal-out and apical-out organoids
210 was changed to DMEM/F-12 containing ETEC K88 (10^6 CFU). After the invasion for 1 h, the
211 organoids were transferred to DMEM/F-12 containing 200 $\mu\text{g ml}^{-1}$ penicillin/streptomycin for
212 1 h to kill residual extracellular bacteria. Then, the organoids were incubated in DMEM/F-12
213 containing *A. muciniphila* (10^5 CFU) for 1 h to detect the repair effect of *A. muciniphila*. In
214 addition, the organoids in WNT-C59 group were pretreated with the Wnt inhibitor Wnt-C59
215 (100 nM, AdooQ, China) for 24 h prior to damage. After co-cultivation, the organoids were

216 collected and resuspended in 4% paraformaldehyde (PFA, Servicebio, China) at 4°C or
217 RNAiso Plus (Takara, Japan) at -80°C for further analysis. For epithelial barrier integrity, the
218 apical-out organoids were resuspended in a solution of 4 kDa fluorescein isothiocyanate-
219 dextran (FD4) (2 mg ml⁻¹) diluted in DMEM/F-12 without phenol red. The design of
220 organoids' experiment is shown in Figure 1C.

221

222 **Real-time quantitative PCR (RT-qPCR) analysis**

223 Total RNA from intestinal tissue and organoids was extracted using TRIzol method
224 according to the precise instructions and cDNA was synthesized using PrimeScript™ RT
225 Master Mix (Takara, Japan). With cDNA as template, RT-qPCR was performed using TB
226 Green® *Premix Ex Taq*™ (Takara, Japan) on a LightCycler 480 System (Roche, Germany).
227 The real-time primers used in this study are listed in Table S1. The relative mRNA expression
228 of target genes was statistically analyzed based on the 2^{-ΔΔCt} method.

229

230 **Bacterial load and intestinal permeability analyses**

231 The bacterial load of ETEC K88 in piglets' jejunal and colonic mucosa was determined
232 by the absolute quantification. In brief, the gene of ETEC K88 (Genbank Accession:
233 M25302.1) was amplified by PCR (mK88-F: GGAATGGAAAGTTGGTACAGGTCTT,
234 mK88-R: CCGGCATAAGATGCATTCACCTTTC), and the PCR product was analyzed by
235 agarose gel electrophoresis. The specific band was excised and recovered, connected with
236 pGM-T vector, and transformed into high-efficiency chemoreceptor DH-5α cells. After
237 culturing, the plasmid DNA was extracted and sequenced. The RT-qPCR analysis was
238 performed as the description of section 2.5. The copy number of samples was calculated by
239 the copy number of standard and the standard curve.

240 For the detection of ETEC K88 load in mice, fresh feces, jejunum and colon tissue, liver,
241 spleen and kidney were homogenized in sterile normal saline using a tissue homogenizer
242 (Jingxin Industrial Development Co., Ltd., China), then the homogenates were diluted 10-fold
243 continuously, and the dilutions were plated on MacConkey Agar (Qingdao Hope Bio-

244 Technology Company, China). After incubating in aerobic incubator at 37°C for 24 h, the
245 plates were counted three times. The results were presented as Lg CFU g⁻¹ of samples.

246 For intestinal permeability assessment in mice, the serum fluorescence was detected
247 using a SpectraMax M5 plate reader (Molecular Devices, USA) at a 485 nm excitation
248 wavelength and a 535 nm emission wavelength. The standard curve was established from the
249 fluorescence of FD4 at concentrations of 0.005, 0.01, 0.02, 0.04, 0.08, 0.16 0.32, 0.64, 1.28,
250 2.56, 5.12 and 10.24 µg ml⁻¹ to calculate the FD4 concentration.

251 For detection of epithelial barrier integrity in organoids, the apical-out organoids in the
252 FD4 solution were transferred to the slide and instantly imaged live by the laser scanning
253 confocal microscope IX81-FV1000 (Olympus, Japan) with FV10-ASW software (Olympus,
254 Japan).

255

256 **Histology and morphology analyses**

257 Jejunum and colon tissues were collected, fixed in 4% PFA, dehydrated with gradient
258 alcohol and embedded in paraffin. The tissue sections were stained with hematoxylin-eosin
259 (H&E) solution. The indexes related to the morphology of jejunum and colon were measured
260 by using Image Plus (v6.0). Scanning electron microscopy (SEM) and transmission electron
261 microscopy (TEM) were performed according to the procedure of the Bio-ultrastructure
262 Analysis Lab of the Analysis Center of Agrobiolgy and Environmental Sciences, Zhejiang
263 University. In brief, intestinal tissues were fixed in 2.5% glutaraldehyde, washed with PBS
264 three times, postfixed with 1% OsO₄ for 1 h, then dehydrated with gradient alcohol (30%,
265 50%, 70%, 80%, 90%, 95% and 100%) for about 15 min at each step. For SEM, the samples
266 were dehydrated in Hitachi Model HCP-2 critical point dryer, coated with gold-palladium in
267 Hitachi Model E-1010 ion sputter, and observed in Hitachi Model SU-8010 SEM. For TEM,
268 the infiltrated samples were embedded in Spurr resin, sectioned in LEICA EM UC7 ultratome,
269 and sections were stained by uranyl acetate and alkaline lead citrate, then observed in Hitachi
270 Model H-7650 TEM.

271

272 **Immunofluorescence analysis**

273 Jejunum tissues were fixed in 4% PFA, dehydrated, paraffin embedded and sectioned.
274 After antigen retrieval and blocking, the sections were incubated in primary antibodies at 4°C
275 overnight and secondary antibodies at room temperature for 50 min in the dark, followed by
276 staining with DAPI at room temperature for 10 min in the dark. The fixed organoids were
277 incubated in primary antibodies in blocking/permeabilization buffer at room temperature for 4
278 h, and then incubated in secondary antibodies together with DAPI and phalloidin (Servicebio,
279 China) in blocking/permeabilization buffer at room temperature for 2 h in the dark. The
280 fluorescence images were captured using a laser scanning confocal microscope IX81-FV1000
281 (Olympus, Japan) combined with FV10-ASW software (Olympus, Japan). The information of
282 primary and secondary antibodies is shown in Table S2.

283

284 **Western blot analysis**

285 Total protein was extracted by radioimmunoprecipitation assay lysis buffer and protein
286 concentration was determined by a BCA Assay Kit (Thermo Fisher Scientific, USA). Equal
287 protein amounts (60 µg) were electrophoresed on 10% sodium dodecyl sulphate-
288 polyacrylamide gel and the separated proteins were transferred onto the polyvinylidene
289 difluoride membranes (Millipore, USA) The membranes were blocked with Tris-buffered
290 saline with Tween (TBST) containing 5% BSA for 1 h at room temperature, and incubated
291 with the primary antibodies (Table S3) in TBST containing 3% BSA overnight at 4°C. After
292 several times washes in TBST, the membranes were incubated with secondary antibodies
293 (Table S3) in TBST containing 3% BSA for 1 h at room temperature. The protein bands were
294 visualized using SuperSignal® West Dura Extended Duration Substrate (Thermo Fisher
295 Scientific, USA), and quantified by Image J software.

296

297 **Microbiome sequencing analysis**

298 Total DNA was extracted from intestinal contents using the E.Z.N.A.® Stool DNA Kit
299 (D4015, Omega, Inc., USA) according to the manufacturer's instructions. The quality of DNA

300 was detected by agarose gel electrophoresis, and total DNA was quantified by ultraviolet
301 spectrophotometer. Specific primers 341 F (5'-CCTACGGGNGGCWGCAG-3') and 805 R
302 (5'-GACTACHVGGGTATCTAATCC-3') were used for bacterial PCR amplification of 16S
303 rDNA V3-V4 hypervariable region. The PCR products were purified using AMPure XT beads
304 (Beckman Coulter Genomics, USA) and quantified by Qubit (Invitrogen, USA). The
305 amplicon pools were prepared for sequencing and the size and quantity of the amplicon
306 library were assessed on Agilent 2100 Bioanalyzer (Agilent, USA) and the Library
307 Quantification Kit for Illumina (Kapa Biosciences, USA), respectively. The libraries were
308 sequenced on NovaSeq PE250 platform. Samples were sequenced on an Illumina NovaSeq
309 platform according to the manufacturer's recommendations. Paired-end reads were assigned to
310 samples based on their unique barcode and truncated by cutting off the barcode and primer
311 sequence. Paired-end reads were merged using FLASH. Quality filtering on the raw reads
312 were performed under specific filtering conditions to obtain the high-quality clean tags
313 according to the fqtrim (v0.94). Chimeric sequences were filtered using Vsearch software
314 (v2.3.4). After dereplication using DADA2, the Operational Taxonomic Unit (OTU) were
315 constructed by Amplicon Sequence Variants to obtain the final feature table and feature
316 sequence. Species annotation of OTU sequences was performed using the Mothur method
317 with the SSUrRNA database of Silva 132, and multiple sequence alignment was performed
318 using MUSCLE (v3.8.31) software to obtain the phylogenetic relationships of all OTUs
319 sequences. The data of each sample were normalized using a standard of sequence number
320 corresponding to the sample with the least sequences. Subsequent analysis of alpha diversity
321 and beta diversity were all performed based on the output normalized data. Alpha diversity is
322 applied in analyzing complexity of species diversity for a sample through 4 indices, including
323 Chao1, Observed species, Shannon, Simpson, and all these indices in our samples were
324 calculated with QIIME2. Beta diversity was calculated by QIIME2, and the Anosim, principal
325 coordinate analysis (PCoA) and non-metric multidimensional scaling (NMDS) analyses were
326 drawn implemented through R software (v3.5.2) with anosim, WGCNA, stats, ggplot2 and

327 vegan packages. Linear discriminant analysis (LDA) effect size (LEfSe) package was used for
328 LEfSe analysis. Other diagrams were implemented by using the R software (v3.5.2).

329

330 **Quantification of Short chain fatty acids**

331 The colonic contents (50 mg) were homogenized with 0.5 ml dH₂O in ball mill and then
332 centrifuged. The supernatant 1 (0.3 ml) was homogenized with 0.5 ml dH₂O and then
333 centrifuged. The supernatant 2 (0.5 ml) combined with supernatant 1 were mixed with 0.8 ml
334 of 2-Methylvaleric acid as internal standard solution and 0.1 ml 50% H₂SO₄. After
335 centrifuging, the supernatant was transferred into fresh glass vial for Gas chromatography-
336 mass spectrometry analysis, which was performed using an Agilent 7890B gas chromatograph
337 system coupled with an Agilent 5977B mass spectrometer. Short chain fatty acids (SCFA)
338 were identified and quantified by the retention time and standard curves of the standard
339 solutions.

340

341 **Flow cytometry (FC) analysis**

342 Intestinal lamina propria cells were isolated by using Mouse Lamina Propria
343 Dissociation Kit (Miltenyi Biotec, Germany) according to the instruction. For cell surface
344 staining, the cells were incubated with FC block at 2-8°C for 15 min, then were stained with
345 Live/Dead Dye (FVS510, BD Pharmingen, USA) at room temperature for 15 min, followed
346 by washing with Stain Buffer. Cells were incubated with specific fluorescent antibodies
347 (Table S4) at 2-8°C for 30 min to label immune cells. For intracellular factor staining, cells
348 were fixed and permeabilized using Transcription Factor Fix/Prem Buffer at 4°C for 40 min,
349 washed with 1 × Perm/Wash Buffer, and stained with intracellular markers at 4°C for 30 min.
350 The stained cells were washed and resuspended in PBS, and assessed by the 12-color
351 FACSCelesta flow cytometer (Becton, Dickinson and Company, USA). The single cells were
352 first gated on SSC-A vs FSC-A and FSC-A vs FSC-H, and then CD45⁺Live⁺ cells were gated
353 on single cells. The CD45⁺CD3⁻ cells were gated on CD45⁺Live⁺ cells. The CD4⁺ T cells
354 (CD3⁺CD4⁺ cells) were gated on CD45⁺CD3⁻ cells, Tregs (CD25⁺Foxp3⁺ cells), and Th17

355 cells (CD4⁺ROR γ t⁺ cells) were gated on CD3⁺CD4⁺ cells. The CD86⁺CD11C⁺ cells were
356 gated on DC⁺CD3⁻ cells. The data were analyzed using FlowJo software (v10.8.0).

357

358 **Isolation and culture of mouse intestinal crypts**

359 The jejunum proximal to the stomach was harvested immediately after mice were
360 sacrificed. After gently flushing with cold D-PBS (without calcium and magnesium) using
361 injection syringe, the intestinal segment was opened longitudinally and gently washed with
362 cold D-PBS three times. Then, the washed intestine was cut into 2 mm pieces with scissors,
363 which fell into a 50 ml conical tube containing 15 ml cold D-PBS. The rinsing procedure that
364 using the 10 ml serological pipette to gently pipette the intestinal pieces up and down three
365 times and then aspirate off the supernatant and add 15 ml fresh cold D-PBS was repeated 10-
366 15 times until the supernatant was clear. The intestinal pieces were resuspended in 25 ml
367 Gentle Cell Dissociation Reagent (GCDR, StemCellTM Technologies, Canada) and incubated
368 at room temperature for 15 min on a rocking platform. After incubation, the intestinal pieces
369 were resuspended in 10 ml cold D-PBS containing 0.1% BSA, supernatant was filtered
370 through a 70 μ m filter (Corning, USA), and filtrate was collected and labeled as fraction 1.
371 Repeat the above step three times to obtain fractions 2-4. The fractions were centrifuged at
372 290 \times g for 5 min at 4 \square and resuspended in 10 ml cold DMEM/F-12 with 15 mM HEPES.
373 The quality of the fractions was assessed by using an inverted microscope. The fraction which
374 enriched for intestinal crypts was selected, centrifuged and resuspended in equal volume of
375 complete IntestiCultTM Organoid Growth Medium (06005, StemCellTM Technologies, Canada)
376 and Matrigel Matrix. The 50 μ l of the 500-crypt suspension was plated in the center of each
377 well of the pre-warmed 24-well plate. The plate was placed at 37 \square with 5% CO₂ for 10 min
378 and then added 750 μ l complete IntestiCultTM Organoid Growth Medium containing 100 μ g
379 ml⁻¹ penicillin/streptomycin to each well. The culture medium was fully exchanged three
380 times per week. After 7 to 10 days of culture, the organoids were passaged using 1:6 split ratio.
381 The images of organoids were captured using inverted microscope (Nikon, Japan). The
382 surface areas of organoids were measured using ImageJ software (v1.8.0). The forming

383 efficiency (%) = (number of mature organoids growing after 5 days / number of crypts seeded)
384 × 100%.

385

386 **Statistical analysis**

387 Data were statistically analyzed by SPSS (v26.0) software, and all data are presented as
388 means ± standard deviation (SD). *P* value < 0.05 was considered significant. Kolmogorov-
389 Smirnov test was used to determine whether the data followed the normal distribution.
390 Comparisons between two groups were executed by unpaired Student's *t*-test or Mann-
391 Whitney *U*-test, and comparisons among three groups were executed by one-way ANOVA or
392 Kruskal-Wallis followed by Dunn's multiple comparisons.

393

394 **Results**

395 **FMT enhanced the protection of AIMD piglets against ETEC K88 challenge**

396 ETEC K88 infection is a leading cause of diarrhea in humans and animals. We set out to
397 explore whether FMT protected against ETEC K88 challenge. The piglets were randomly
398 assigned to three groups: the control piglets (Con group), the ETEC K88 infected piglets (EP
399 group) and the ETEC K88 infected piglets with FMT treatment (EF group). As shown in
400 Figure 2A and 2B, decreased ADG and increased diarrhea score were observed in AIMD
401 piglets at day 3 and day 6 after ETEC K88 infection, and these symptoms were relieved by
402 FMT treatment. We next detected the pathogen colonization in mucosal tissues and found that
403 FMT significantly decreased the copies of ETEC K88 in the jejunal and colonic mucosa
404 (Figure 2C). To address whether FMT could protect intestinal barrier against ETEC K88
405 infection, intestinal barrier integrity and inflammatory cytokine levels were detected. FMT
406 decreased the expression of proinflammatory cytokines (*TNF-α*, *IL-1β* and *IL-6*) and
407 increased levels of anti-inflammatory cytokines (*IL-10* and *TGF-β1*) in the jejunum (*P* < 0.01,
408 Figure 2D). Jejunal scanning electron microscopy showed that the villi (Figure 3A top) in
409 ETEC K88 infected piglets were short and coarse, and there existed obvious rod-shaped
410 bacterial adhesion on the surface of microvilli (Figure 3A bottom), while FMT reversed villi

411 and microvilli injury caused by ETEC K88. In addition, the reduced mRNA and protein levels
412 of the tight junctions (ZO-1, claudin and occludin) and adheren junctions (β -catenin and E-
413 cadherin) caused by ETEC K88 challenge were also reversed by FMT treatment in the
414 jejunum (Figure 3B-C). We then evaluated the expression of Mucin 2 (MUC2) in the jejunum
415 using immunofluorescence staining. As shown in Figure 3D, ETEC K88 infection reduced the
416 expression of MUC2, which was significantly increased following FMT administration. These
417 results indicated that FMT enhanced the protection of AIMD piglets against ETEC K88
418 challenge.

419

420 ***A. muciniphila* and *B. fragilis* were identified as two key strains in FMT**

421 We next assessed the variation of gut microbiota and SCFA metabolites in ETEC K88-
422 challenged piglets. The alpha diversity indexes were increased after FMT treatment (Figure
423 S1A-B). The PCoA and NMDS showed that gut microbiota between two groups clustered
424 separately (Figure S1C-D). The Anosim analysis ($R = 0.396$, $P = 0.02$) and UPGMA
425 clustering analysis also indicated that FMT altered the structure of the gut microbiota in
426 ETEC K88-challenged piglets (Figure 4A-B). LEfSe analysis verified that *B. fragilis* and
427 *Akkermansia* were changed significantly with an upper 4 LDA score after FMT administration
428 (Figure 4C). We compared the OTU sequence of *Akkermansia* in the National Center for
429 Biotechnology Information database by using Blast method based on Best Hit algorithm, and
430 the result was *A. muciniphila*. Furthermore, FMT significantly increased the production of
431 SCFA metabolites, including acetic acid, propionic acid, butyric acid, isobutyric acid,
432 isovaleric acid and hexanoic acid (Figure 4D). These results demonstrated that FMT regulated
433 gut microbiota and SCFA metabolites in ETEC K88-challenged piglets. *A. muciniphila* and *B.*
434 *fragilis* were identified as two strains that may play key roles in FMT.

435

436 ***A. muciniphila* and *B. fragilis* maintain intestinal barrier function of ETEC-induced** 437 **mice**

438 We further investigated whether these two strains exerted protective effects on ETEC
439 infection in AIMD mice model. Mice were randomly assigned to four groups: the control
440 mice (C group), the ETEC K88 infected mice (E group), the ETEC K88 infected mice treated
441 with *A. muciniphila* (A group) and the ETEC K88 infected mice treated with *B. fragilis* (B
442 group). As shown in Figure S2A and 5A, ETEC K88 infection led to weight loss and intestinal
443 morphology damage, which was relieved by *A. muciniphila* and *B. fragilis* treatment.
444 Correspondingly, scanning electron microscopy showed that *A. muciniphila* and *B. fragilis*
445 increased the height and number of microvilli and ameliorated the distribution of intercellular
446 junction in the jejunum and colon (Figure 5B). In addition, the relative mRNA and protein
447 expressions of MUC2 were significantly increased in the jejunum of *A. muciniphila* and *B.*
448 *fragilis* treated mice (Figure 5C). However, only *A. muciniphila* could upregulated MUC2
449 protein expression in the colon of treated mice (Figure 5C). Furthermore, we investigated the
450 diffusion of ETEC K88 in feces and organs after infection. ETEC K88 infection surged the
451 number of *Escherichia coli* in the feces, jejunum, colon, liver, spleen and kidney (Figure S2B).
452 *A. muciniphila* and *B. fragilis* treatment dramatically decreased the amount of ETEC K88 in
453 these tissues (Figure S2B), indicating a reduced translocation of ETEC K88 in the tissues and
454 organs. The concentration of FD4 in the serum has been commonly used as an indicator of
455 intestinal permeability. As shown in Figure S2C, *A. muciniphila* and *B. fragilis* significantly
456 decreased serum FD4 concentration, indicating *A. muciniphila* and *B. fragilis* enhanced
457 intestinal barrier integrity.

458 ETEC K88 adheres to intestinal epithelial cells and induces gut inflammation. As
459 demonstrated in Figure 6A, ETEC K88 decreased the relative mRNA expression of anti-
460 inflammatory cytokines *IL-10* and *TGF- β* and increased levels of pro-inflammatory cytokines
461 *TNF- α* , *IL-1 β* , *IL-6* and *IFN- γ* , which was reversed in A and B groups, indicating that *A.*
462 *muciniphila* and *B. fragilis* ameliorated ETEC K88-induced intestinal inflammation. Intestinal
463 inflammatory response is closely related to immune cells. Treg cells secrete anti-inflammatory
464 cytokines *IL-10* and *TGF- β* to alleviate intestinal inflammation. Conversely, Th17 cells
465 produce pro-inflammatory cytokines, such as *IFN- γ* and *IL-17*, which aggravate intestinal

466 inflammation. The dynamic balance of Treg and Th17 cells plays an important role in
467 intestinal immunity. Therefore, we used flow cytometry to analyze the proportion of the
468 immune cells isolated from jejunal lamina propria in the innate and adaptive immune system.
469 Treg cells were labeled with CD25⁺Foxp3⁺ cells, Th17 cells were labeled with CD4⁺ROR γ t⁺
470 cells, and mature dendritic cells were labeled with CD86⁺CD11C⁺ cells. ETEC K88 infection
471 significantly decreased the proportion of Treg cells and mature dendritic cells and increased
472 the proportion of Th17 cells, while oral administration of *A. muciniphila* or *B. fragilis*
473 significantly reduced the proportion of Th17 cells and increased the proportion of mature
474 dendritic cells (Figure 6B). Moreover, compared with E group, the proportion of Treg cells in
475 A group was significantly increased ($P < 0.01$), and the proportion of Treg cells in the B
476 group had an increasing trend ($P = 0.59$), indicating FMT maintained the proportion of
477 Treg/Th17 cells in ETEC K88-infected mice.

478

479 ***A. muciniphila* accelerated intestinal epithelial proliferation**

480 Since oral administration of *A. muciniphila* and *B. fragilis* mitigated intestinal mucosal
481 injury, we set out to explore their effects on the proliferation and differentiation of intestinal
482 epithelium. ETEC K88 infection prominently decreased *Ki67* and *Lyz* mRNA expression and
483 the number of Ki67⁺ cells and Lyz⁺ Paneth cells in the crypt of the jejunum (Figure 7A and
484 7B). *A. muciniphila* and *B. fragilis* increased *Ki67* and *Lyz* mRNA expression and the number
485 of Ki67⁺ cells. However, only *A. muciniphila* enhanced the number of Lyz⁺ Paneth cells,
486 suggesting that *A. muciniphila* accelerated the proliferation and differentiation of intestinal
487 epithelial cells. Lgr5-labeled active intestinal stem cells are the driving force of intestinal
488 epithelial proliferation and differentiation after intestinal injury. ETEC K88 infection
489 significantly increased the relative mRNA expression of *Lgr5*, *Wnt3*, *Axin2*, *Ctnnb1* in
490 jejunum mucosa and had no significant impact on *Notch1* and *Hes1* expression (Figure 7C). *A.*
491 *muciniphila* and *B. fragilis* inhibited the upregulation of *Lgr5*, *Wnt3*, *Axin2* and *Ctnnb1* at
492 transcriptional level caused by ETEC K88 infection and had no significant effect on *Notch1*
493 and *Hes1* levels. Western blot analysis also showed that *A. muciniphila* and *B. fragilis*

494 inhibited the upregulation Lgr5, Wnt3, Active β -catenin, c-Myc and CyclinD1 at protein level,
495 and the effect of *A. muciniphila* was better than that of *B. fragilis* (Figure 7D). These results
496 implied that *A. muciniphila* regulated the expression of intestinal stem cells in ETEC K88-
497 challenged mice and regulated Wnt/ β -catenin signaling pathway rather than Notch signaling
498 pathway.

499 We next isolated jejunal crypt from mice and explore whether *A. muciniphila* or *B.*
500 *fragilis* influenced the ability of intestinal stem cells growing into intestinal organoids *ex vivo*.
501 In ETEC K88-infected mice, the crypts formed into undifferentiated spherical organoids,
502 while in *A. muciniphila* or *B. fragilis* treated mice, the crypts generated mature organoids with
503 bud structure (Figure 8A). We statistically analyzed the surface area and forming efficiency of
504 the intestinal organoids. As shown in Figure 8B, the organoids derived from ETEC K88-
505 infected mice had smaller surface area and lower forming efficiency than those from control
506 mice. *A. muciniphila* treatment led to larger surface area and higher forming efficiency of the
507 intestinal organoids. The surface area of intestinal organoids in B group was larger than that in
508 E group, while there was no significant difference in forming efficiency between these two
509 groups. Meanwhile, the relative mRNA expression of genes related to the proliferation and
510 differentiation at the intestinal organoid level was consistent with the results of jejunal
511 mucosa *in vivo* (Figure 8C). These results suggested that *A. muciniphila* accelerated intestinal
512 epithelial proliferation and regulated Wnt/ β -catenin signaling pathway *ex vivo*.

513

514 ***A. muciniphila* protected intestinal organoids against ETEC infection via Wnt signaling**

515 To explore the effects and mechanisms of *A. muciniphila* on ETEC K88 infection *in vitro*,
516 the porcine intestinal organoids were infected with ETEC K88 (ETEC group), and then co-
517 cultured with *A. muciniphila* (AKK group). Wnt inhibitor Wnt-C59 was added to explore
518 whether *A. muciniphila* acted through Wnt/ β -catenin signaling pathway (WNT-C59 group),
519 and porcine intestinal organoids without any treatment were used as blank control (CON
520 group). The relative mRNA expression of *villin*, *ZO-1*, *Ki67*, *Lyz*, *MUC2*, *Lgr5*, *Wnt3a*, β -
521 *catenin* and the fluorescence intensity of villin, Ki67, Lgr5, Wnt3a and β -catenin in basal-out

522 intestinal organoids were significantly down-regulated upon ETEC exposure (Figure 9A-G).
523 *A. muciniphila* upregulated Lgr5, Wnt3a and β -catenin expression in ETEC-infected
524 organoids, while these effects were inhibited by Wnt-C59 treatment (Figure 9A-G). The
525 results suggested that *A. muciniphila* increased the number of intestinal stem cells and
526 activated Wnt signaling, but did not promote the proliferation and differentiation of basal-out
527 gut organoids. In basal-out intestinal organoid models, the intestinal epithelium was in the
528 interior of organoid spheroid, which restricted the interaction between intestinal epithelium
529 and *A. muciniphila*. Therefore, we reversed the polarity of basal-out intestinal organoids by
530 removing the Matrigel from the culture system and suspending intestinal organoids in the
531 culture (Figure S3A). In apical-out intestinal organoids, the apical surface was outward to
532 make it accessible to *A. muciniphila*. Under confocal microscopy, the F-actin of basal-out
533 intestinal organoid was located in the inside of the spheroids, while the F-actin of the apical-
534 out intestinal organoid was outside the spheroids, indicating that the polar reversal intestinal
535 organoid model was successfully constructed (Figure S3B). We conducted FD4 permeation
536 test in apical-out intestinal organoid model, and co-cultivation with *A. muciniphila* restored
537 the epithelial barrier integrity of organoids challenged by ETEC K88 (Figure 10A, H). *A.*
538 *muciniphila* not only increased the mRNA expression of *ZO-1*, *Lyz* and *MUC2* in the ETEC
539 K88 infected apical-out intestinal organoids, but also up-regulated the protein expression of
540 villin, Wnt3a, β -catenin and the number of Lgr5⁺ and Ki67⁺ cells (Figure 10B-G, I). Moreover,
541 *A. muciniphila* also relieved the inflammatory response of the ETEC K88 infected apical-out
542 intestinal organoids, as determined by decreasing proinflammatory cytokines, inducing *TNF- α* ,
543 *IL-1 β* , *IL-6* and *IFN- γ* , and increasing anti-inflammatory cytokines *IL-10* and *TGF- β* (Figure
544 10J). However, the moderating effect of *A. muciniphila* on the apical-out intestinal organoids
545 disappeared after Wnt-C59 exposure. Taken together, *A. muciniphila* accelerated the
546 proliferation and differentiation of the intestinal stem cells and ameliorated the intestinal
547 barrier injury and inflammation induced by ETEC K88. *A. muciniphila* protected intestinal
548 organoids against ETEC infection via Wnt signaling.

549

550 Discussion

551 The homeostasis of gut microbiota is a major contributor to host health. Intestinal
552 dysbiosis increases intestinal colonization of antibiotic-resistant and pathogenic bacteria.
553 Antibiotic treatment is the most drastic exposure leading to gut dysbiosis and pathogen
554 invasion (*Andremont et al., 2021*). Early-life exposure to antibiotic leads to gut microbiota
555 dysbiosis and impair host immune system maturation, which may even last for long periods
556 throughout life (*Nguyen et al., 2020*). Researchers have made a lot of attempts to prevent or
557 inhibit antibiotic-induced dysbiosis. Our previous study showed that FMT alleviates early-
558 life antibiotic-induced gut microbiota dysbiosis and mucosa injuries in a neonatal piglet
559 model (*Ma et al., 2021*). Our present study aimed to investigate whether FMT increases early-
560 life antibiotic induced neonatal piglet against pathogen invasion. ETEC K88 is one of the
561 most common pathogens in humans and animals and causes intestinal inflammation and
562 diarrhea symptoms (*Sun and Kim et al., 2017*). Studies demonstrated that ETEC K88
563 infection led to pro-inflammatory cytokine upregulation and intestinal mucosal barrier injury
564 (*Wang et al., 2020; Xie et al., 2021*). In ETEC-induced neonatal piglets, ZO-1 and Claudin-2
565 levels in ileum of were significantly decreased after ETEC K88 infection (*Xie et al., 2021*). In
566 accordance with the above results, the present study showed that ETEC K88 infection
567 increased the expression of pro-inflammatory cytokines and reduced the expression of
568 intercellular junction proteins in AIMD piglets. Since FMT has been successful in treating
569 *Clostridioides difficile* infection and maintaining gut barrier, emerging investigation has been
570 focused on other diseases (*Cammarota et al., 2017*). *Geng et al. (2018)* demonstrated that
571 FMT diminished the inflammatory response and the destruction of epithelial integrity in
572 piglets challenged with lipopolysaccharide. In the present study, we found that FMT
573 dampened ETEC K88-induced pro-inflammatory cytokines upregulation and improved the
574 intestinal morphology. In addition, the number of ETEC K88 in jejunal and colonic mucosa
575 was significantly decreased following FMT, which was consistent with the observation of
576 jejunal microvilli under SEM, showing the absence of rod-shaped bacterial adhesion in FMT
577 treatment. ETEC infection was reported to reduce the MUC2 expression by destroying goblet

578 cells or directly degrading MUC2, thereby damaging the integrity of the intestinal epithelial
579 barrier (*Luo et al., 2014*). Our results demonstrated that FMT enhanced the expression of
580 MUC2 and increased the expression of ZO-1, claudin, occludin, β -catenin and E-cadherin at
581 mRNA and protein levels, indicating that FMT improved the intercellular junctions between
582 intestinal epithelial cells and restored the integrity of the intestinal mucosal barrier to reduce
583 the colonization and invasion of ETEC K88.

584 Intestinal microbiota plays a key role in maintaining gut mucosal barrier and resistance
585 to pathogen invasion (*Chelakkot et al., 2018*). Antibiotic-induced gut microbiota-disorders
586 have been reported to disrupt gut barrier and increase the susceptibility of host to pathogenic
587 microbes (*Wlodarska et al., 2011*). So, we further probed the changes of gut microbiota in
588 AIMD piglets infected with ETEC K88. The results showed that FMT regulated gut
589 microbiota and SCFAs metabolism in ETEC K88-challenged piglets. LEfSe analysis
590 manifested that *B. fragilis* and *A. muciniphila* were the key differential bacteria between three
591 groups. *A. muciniphila* utilizes mucin as the only carbon and nitrogen source for its growth in
592 the gut, and its metabolite SCFAs can facilitate MUC2 secretion by goblet cells to maintain
593 the dynamic balance of intestinal mucus layer (*Ottman et al., 2017*). *A. muciniphila*
594 negatively correlated with many diseases, including diabetes, obesity and inflammatory bowel
595 diseases (*Belzer C and de Vos, 2012; Castro-Mejía et al., 2016; Plovier et al., 2017*). It has
596 been reported that *A. muciniphila* effectively inhibited intestinal inflammatory response and
597 elevated epithelial barrier function (*Everard et al., 2013; Li et al., 2016; Zhang et al., 2018*).
598 Meanwhile, *Bacteroides fragilis* is one of the symbiotic anaerobes within the mammalian gut
599 and is also an opportunistic pathogen which often isolated from clinical specimens (*Sun et al.,*
600 *2019*). Although it was initially thought to be pathogenic, in the long-term evolution process,
601 *Bacteroides fragilis* colonized in the gut has established a friendly relationship with the host,
602 which is an essential component for maintaining the health of the host, especially for obesity,
603 diabetes and immune deficiency diseases (*Troy and Kasper, 2010*). *B. fragilis* could
604 decompose mucin by lipid-anchored enzymes and interact with intestinal epithelial cells,
605 thereby altering intestinal permeability and repairing intestinal epithelial barrier (*Donaldson*

606 *et al.*, 2016; Hsiao *et al.*, 2013). Deng *et al.* (2016) reported that *B. fragilis* altered
607 macrophage phenotype and increased the phagocytosis of macrophages to restrain pathogens
608 colonization. Hence, we speculated that FMT increased the relative abundance of *A.*
609 *muciniphila* and *B. fragilis* in the intestine and alleviate intestinal barrier injury and intestinal
610 inflammation caused by ETEC K88 infection.

611 Since *A. muciniphila* and *B. fragilis* were identified as two strains that may play key
612 roles in FMT, we further investigate whether *A. muciniphila* and *B. fragilis* exerted protective
613 effect on ETEC K88 infection in AIMD mice model. We found that *A. muciniphila* and *B.*
614 *fragilis* maintained normal gut morphology after ETEC K88 infection, repaired the integrity
615 of intestinal mucosal barrier as evidenced by the reduced FD4 concentration in serum,
616 colonized in the intestine and inhibit the translocation of ETEC K88, and reduced the
617 intestinal inflammation, which may have been attributed to the increased proportion of Treg
618 cells and mature dendritic cells and the decreased proportion of Th17 cells. These results are
619 consistent with the protective role of *A. muciniphila* and *B. fragilis* in dextran sulphate sodium
620 salt induced enteritis model (Bian *et al.*, 2019; Wang *et al.*, 2021; Zhai *et al.*, 2019). Intestinal
621 stem cell renewal is vital to maintaining the gut barrier. Ki67 is widely expressed in
622 proliferating cells and presents a reliable indicator of cell proliferation activity (Zheng *et al.*,
623 2010). Ki67 reaches its peak during the division stage with short half-life period and easy
624 degradation (Zheng *et al.*, 2010). In our study, *A. muciniphila* and *B. fragilis* increased the
625 number of Ki67⁺ cells and the mRNA expression of *Lyz*, suggesting that *A. muciniphila* and *B.*
626 *fragilis* accelerated the proliferation and differentiation of intestinal epithelium. Paneth cells
627 not only produce antimicrobial peptides and express key niche signals that regulate stem cells,
628 but also secrete activators that dynamically modulate Wnt/ β -catenin signaling pathway (Hou
629 *et al.*, 2020). The Wnt/ β -catenin signaling pathway is essential for the proliferation and
630 differentiation of intestinal stem cells (Ring *et al.*, 2014). When the Wnt receptors are
631 activated, the multiprotein degradation complex is rapidly inhibited, which allows β -catenin
632 to accumulate and subsequently migrate to the nucleus and binds to the transcription factors
633 of T cell factor family and lymphoid enhancer-binding factor family to drive the expression of

634 genes that regulate the stem cells, including Lgr5, c-Myc and Cyclin D1 (Niehrs, 2012). The
635 c-Myc and Cyclin D1 are cyclins that positively regulate cell cycle from the G1 phase to S
636 phase, thus inducing cell cycle progression and promote cell proliferation (Shi et al., 2015).
637 Zhu et al. (2020) reported that *A. muciniphila* restored intestinal mucosal damage with the
638 accelerated proliferation of intestinal epithelium through Wnt/ β -catenin signaling pathway,
639 thus relieving infection caused by *Salmonella pullorum* in chicks. In the present study, *A.*
640 *muciniphila* moderately activated Wnt/ β -catenin signaling pathway and maintain the suitable
641 expression of Wnt, Active- β -catenin, Lgr5, c-Myc and Cyclin D1. Consistent with the *in vivo*
642 results, *ex vivo* results of mouse intestinal organoids also demonstrated that *A. muciniphila*
643 repaired the damaged intestinal epithelium caused by the ETEC K88 infection by modulating
644 the Wnt/ β -catenin signaling pathway. Simultaneously, *B. fragilis* also avoid the overactivation
645 of the Wnt/ β -catenin signaling pathway caused by the ETEC K88 infection, while the impact
646 of *B. fragilis* was not as obvious as *A. muciniphila*.

647 Intestinal organoid is an ideal model for studying the interaction between intestinal
648 epithelium and microorganisms *in vitro*, which can eliminate the complexity of animal models
649 and avoid the unicity of the traditional intestinal epithelial cells (Yin et al., 2019). In order to
650 further verify whether *A. muciniphila* attenuated ETEC K88 infection through Wnt/ β -catenin
651 signaling pathway, basal-out and apical-out porcine intestinal organoid models was used.
652 Notably, we found that the ETEC K88 infection down-regulated Wnt/ β -catenin signaling
653 pathway *in vitro*, which was inconsistent with the results *in vivo*. A recent study showed that
654 the addition of 400 ng ml⁻¹ STp, an enterotoxin of ETEC, could suppress Wnt/ β -catenin
655 signaling pathway of porcine intestinal organoids (Zhou et al., 2021). It is speculated that the
656 reason for the difference results might be related to the difference in the processing time of the
657 *in vivo* and *in vitro* treatment. In spite of the slight stimulation of *A. muciniphila* on the
658 proliferation and differentiation of infected intestinal organoids, *A. muciniphila* up-regulated
659 the Wnt/ β -catenin signaling pathway and had protective effects on intestinal stem cells. In
660 basal-out intestinal organoid models, the intestinal epithelium was in the interior of organoid
661 spheroid, which restricted the interaction between intestinal epithelium and *A. muciniphila*.

662 *Co et al. (2019)* first established the intestinal organoid model with polarity reversal in human
663 and mouse and evaluated the infection effects of the invasive pathogens with different
664 polarity-specific patterns, *Salmonella enterica* serovar *Typhimurium* and *Listeria*
665 *monocytogenes*, on polarity reversal intestinal organoids. Subsequently, *Li et al. (2020)* first
666 applied the porcine intestinal organoids with polarity reversal to investigate the infectivity and
667 antiviral immune responses of porcine transmissible gastroenteritis virus. In addition, studies
668 on host-pathogen interactions using polarity reversal intestinal organoids have also been
669 reported in the sheep and chickens (). But up to now, there are few reports on the interaction
670 between host and symbiotic microorganism using polarity reversal intestinal organoids. Here,
671 we utilized porcine polarity reversal intestinal organoids to make *A. muciniphila* directly
672 interacting with the intestinal epithelium. Our results showed that *A. muciniphila* alleviated
673 the injury of polarity reversal intestinal organoids induced by ETEC K88. In agreement with
674 the *in vivo* results, *A. muciniphila* restrain the intestinal inflammation caused by the ETEC
675 K88 infection in polarity reversal intestinal organoids. Additionally, the alleviatory effect of *A.*
676 *muciniphila* on ETEC K88 infection via the Wnt/ β -catenin signaling pathway was confirmed
677 with the addition of Wnt inhibitor Wnt-C59. The promoted proliferation and differentiation in
678 the basal-out and apical-out intestinal organoids after co-culturing with *A. muciniphila* were
679 reversed with Wnt-C59.

680 In conclusion, we found that FMT relieved intestinal inflammation and improved
681 intestinal barrier function in AIMD piglets infected with ETEC K88. *A. muciniphila* was
682 identified as key strain in FMT to promote the proliferation and differentiation of intestinal
683 stem cells by mediating the Wnt/ β catenin signaling pathway. The study revealed the possible
684 mechanism that FMT alleviates the intestinal barrier injury.

685

686 **DECLARATIONS**

687 **Ethics approval and Consent to participate**

688 All animal experiments were performed according to the guidelines of the Animal Care
689 Committee of Zhejiang University School of Medicine (permit number SYXK 2012-0178).

690 The animal care protocol was approved by the Local Committee of Animal Use following the
691 Guide for the Care and Use of Laboratory Animals (NIH publication 86-23 revised 1985).

692 **Consent for publication**

693 Not applicable.

694 **Availability of data and material**

695 The raw sequences derived from microbiome analysis for this study can be found in the
696 Sequence Read Archive (SRA) (<https://www.ncbi.nlm.nih.gov/sra/PRJNA837047>). And all
697 datasets analyzed in the present study are available from the corresponding author on
698 reasonable request.

699 **Competing interests**

700 The authors declared that the work was carried out in the absence of any commercial or
701 financial relationships that could be construed as a potential conflict of interest.

702 **Funding**

703 This research was supported by the National Natural Science Foundation of China (grant
704 number 32172765).

705 **Acknowledgments**

706 We appreciated the Experimental Teaching Center, College of Animal Science, Zhejiang
707 University for providing the AW400SG anaerobic workstations.

708

709 **References**

- 710 **An DD**, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, Lu X, Zeissig S, Blumberg RS, Kasper
711 DL. 2014. Sphingolipids from a Symbiotic Microbe Regulate Homeostasis of Host Intestinal Natural
712 Killer T Cells. *Cell* **156**(1-2):123-133. DOI: <https://doi.org/10.1016/j.cell.2013.11.042>, PMID: 24439373.
- 713 **Andremont A**, Cervesi J, Bandinelli PA, Vitry F, de Gunzburg J. 2021. Spare and repair the gut microbiota
714 from antibiotic-induced dysbiosis: state-of-the-art. *Drug Discovery Today* **26**(9):2159-2163. DOI:
715 <https://doi.org/10.1016/j.drudis.2021.02.022>, PMID: 33639249.
- 716 **Belzer C**, de Vos WM. 2012. Microbes inside-from diversity to function: the case of *Akkermansia*. *ISME*
717 *Journal* **6**(8):1449-1458. DOI: <https://doi.org/10.1038/ismej.2012.6>, PMID: 22437156.
- 718 **Beumer J**, Clevers H. 2021. Cell fate specification and differentiation in the adult mammalian intestine.
719 *Nature Reviews Molecular Cell Biology* **22**(1):39-53. DOI: <https://doi.org/10.1038/s41580-020-0278-0>,
720 PMID: 32958874.
- 721 **Bian XY**, Wu WR, Yang LY, Lv LX, Wang Q, Li YT, Ye JZ, Fang DQ, Wu JJ, Jiang XW, Shi D, Li LJ.
722 2019. Administration of *Akkermansia muciniphila* Ameliorates Dextran Sulfate Sodium-Induced
723 Ulcerative Colitis in Mice. *Frontiers in Microbiology* **10**:2259. DOI:
724 <https://doi.org/10.3389/fmicb.2019.02259>, PMID: 31632373.
- 725 **Borody TJ**, Eslick GD, Clancy RL. 2019. Fecal microbiota transplantation as a new therapy: from
726 *Clostridioides difficile* infection to inflammatory bowel disease, irritable bowel syndrome, and colon
727 cancer. *Current Opinion in Pharmacology* **49**:43-51. DOI: <https://doi.org/10.1016/j.coph.2019.04.017>,
728 PMID: 31173991.
- 729 **Buffie CG**, Pamer EG. 2013. Microbiota-mediated colonization resistance against intestinal pathogens.
730 *Nature Reviews Immunology* **13**(11):790-801. DOI: <https://doi.org/10.1038/nri3535>, PMID: 24096337.
- 731 **Cammarota G**, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C,
732 Hart A, Segal J, Aloï M, Masucci L, Molinaro A, Scaldaferrì F, Gasbarrini G, Lopez-Sanroman A, Link
733 A, De Groot P, de Vos WM, Hoegenauer C, Malfertheiner P, Mattila E, Milosavljevic T, Nieuwdorp M,
734 Sanguinetti M, Simren M, Gasbarrini A. 2017. European consensus conference on faecal microbiota
735 transplantation in clinical practice. *Gut* **66**(4):569-580. DOI: <https://doi.org/10.1136/gutjnl-2016-313017>,
736 PMID: 28087657.
- 737 **Canfora EE**, Meex RCR, Venema K, Blaak EE. 2019. Gut microbial metabolites in obesity, NAFLD and
738 T2DM. *Nature Reviews Endocrinology* **15**(5):261-273. DOI: <https://doi.org/10.1038/s41574-019-0156-z>,
739 PMID: 30670819.
- 740 **Castro-Mejía J**, Jakešević M, Krych L, Nielsen DS, Hansen LH, Sondergaard BC, Kvist PH, Hansen AK,
741 Holm TL. 2016. Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut
742 Microbiota Changes in an Experimental Colitis Model. *Gastroenterology Research and Practice*
743 **2016**:4953120. DOI: <https://doi.org/10.1155/2016/4953120>, PMID: 26880890.
- 744 **Chelakkot C**, Ghim J, Ryu SH. 2018. Mechanisms regulating intestinal barrier integrity and its
745 pathological implications. *Experimental & Molecular Medicine* **50**(8):1-9. DOI:
746 <https://doi.org/10.1038/s12276-018-0126-x>, PMID: 30115904.
- 747 **Co JY**, Margalef-Català M, Monack DM, Amieva MR. 2021. Controlling the polarity of human
748 gastrointestinal organoids to investigate epithelial biology and infectious diseases. *Nature Protocols*
749 **16**(11):5171-5192. DOI: <https://doi.org/10.1038/s41596-021-00607-0>, PMID: 34663962.

- 750 **Co JY**, Margalef-Català M, Li XN, Mah AT, Kuo CJ, Monack DM, Amieva MR. 2019. Controlling
751 Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions. *Cell Reports* **26**(9):2509-
752 2520. DOI: <https://doi.org/10.1016/j.celrep.2019.01.108>, PMID: 30811997.
- 753 **Colman RJ**, Rubin DT. 2014. Fecal microbiota transplantation as therapy for inflammatory bowel disease:
754 A systematic review and meta-analysis. *Journal of Crohns & Colitis* **8**(12):1569-1581. DOI:
755 <https://doi.org/10.1016/j.crohns.2014.08.006>, PMID: 25223604.
- 756 **Deng HM**, Li ZC, Tan YF, Guo ZB, Liu YY, Wang Y, Yuan Y, Yang RF, Bi YJ, Bai Y, Zhi FC. 2016. A
757 novel strain of *Bacteroides fragilis* enhances phagocytosis and polarises M1 macrophages. *Scientific*
758 *Reports* **6**:29401. DOI: <https://doi.org/10.1038/srep29401>, PMID: 27381366.
- 759 **Donaldson GP**, Lee SM, Mazmanian SK. 2016. Gut biogeography of the bacterial microbiota. *Nature*
760 *Reviews Microbiology* **14**(1):20-32. DOI: <https://doi.org/10.1038/nrmicro3552>, PMID: 26499895.
- 761 **Dubreuil JD**. 2021. Pig vaccination strategies based on enterotoxigenic *Escherichia coli* toxins. *Brazilian*
762 *Journal of Microbiology* **52**(4):2499-2509. DOI: <https://doi.org/10.1007/s42770-021-00567-3>, PMID:
763 34244980.
- 764 **Everard A**, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG,
765 Delzenne NM, de Vos WM, Cani PD. 2013. Cross-talk between *Akkermansia muciniphila* and intestinal
766 epithelium controls diet-induced obesity. *Proceedings of the National Academy of Sciences of the United*
767 *States of America* **110**(22):9066-9071. DOI: <https://doi.org/10.1073/pnas.1219451110>, PMID: 23671105.
- 768 **Flint H**, Scott KP, Louis P, Duncan SH. 2012. The role of the gut microbiota in nutrition and health. *Nature*
769 *Reviews Gastroenterology & Hepatology* **9**(10):577-589. DOI: <https://doi.org/10.1038/nrgastro.2012.156>,
770 PMID: 22945443.
- 771 **Francino MP**. 2016. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of
772 Resistances. *Frontiers in Microbiology* **6**:1543. DOI: <https://doi.org/10.3389/fmicb.2015.01543>, PMID:
773 26793178.
- 774 **Geng SJ**, Cheng SS, Li Y, Wen ZS, Ma X, Jiang XM, Wang YZ, Han XY. 2018. Faecal Microbiota
775 Transplantation Reduces Susceptibility to Epithelial Injury and Modulates Tryptophan Metabolism of the
776 Microbial Community in a Piglet Model. *Journal of Crohns & Colitis* **12**(11):1359-1374. DOI:
777 <https://doi.org/10.1093/ecco-jcc/jjy103>, PMID: 30010734.
- 778 **Ghosh S**, Whitley CS, Haribabu B, Jala VR. 2021. Regulation of Intestinal Barrier Function by Microbial
779 Metabolites. *Cellular and Molecular Gastroenterology and Hepatology* **11**(5):1464-1482. DOI:
780 <https://doi.org/10.1016/j.jcmgh.2021.02.007>, PMID: 33610769.
- 781 **Hou QH**, Dong YY, Yu QH, Wang B, Le S, Guo YM, Zhang BK. 2020. Regulation of the Paneth cell niche
782 by exogenous L-arginine couples the intestinal stem cell function. *FASEB Journal* **34**(8): 10299-10315.
783 DOI: <https://doi.org/10.1096/fj.201902573RR>, PMID: 32725957.
- 784 **Hsiao EY**, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE,
785 Petrosino JF, Patterson PH, Mazmanian SK. 2013. Microbiota Modulate Behavioral and Physiological
786 Abnormalities Associated with Neurodevelopmental Disorders. *Cell* **155**(7):1451-1463. DOI:
787 <https://doi.org/10.1016/j.cell.2013.11.024>, PMID: 24315484.
- 788 **Li J**, Lin SQ, Vanhoutte PM, Woo CW, Xu AM. 2016. *Akkermansia Muciniphila* Protects Against
789 Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe^{-/-} Mice.
790 *Circulation* **133**(24):2423-2446. DOI: <https://doi.org/10.1161/CIRCULATIONAHA.115.019645>, PMID:
791 27143680.

- 792 **Li Y**, Yang N, Chen JN, Huang X, Zhang N, Yang SS, Liu G, Liu GL. 2020. Next-Generation Porcine
793 Intestinal Organoids: an Apical-Out Organoid Model for Swine Enteric Virus Infection and Immune
794 Response Investigations. *Journal of Virology* **94**(21):e01006-20. DOI: [https://doi.org/10.1128/JVI.01006-](https://doi.org/10.1128/JVI.01006-20)
795 [20](https://doi.org/10.1128/JVI.01006-20), PMID: 32796075.
- 796 **Luo HM**, Li MX, Wang F, Yang YF, Wang Q, Zhao YS, Du FK, Chen Y, Shen J, Zhao QY, Zeng JP, Wang
797 SP, Chen MJ, Li XB, Li WP, Sun YH, Gu L, Wen QL, Xiao ZG, Wu X. 2022. The role of intestinal stem
798 cell within gut homeostasis: Focusing on its interplay with gut microbiota and the regulating pathways.
799 *International Journal of Biological Sciences* **18**(13):5185-5206. DOI: <https://doi.org/10.7150/ijbs.72600>,
800 PMID: 35982910.
- 801 **Luo QW**, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J, Fleckenstein JM. 2014.
802 Enterotoxigenic *Escherichia coli* Secretes a Highly Conserved Mucin-Degrading Metalloprotease To
803 Effectively Engage Intestinal Epithelial Cells. *Infection and Immunity* **82**(2):509-521. DOI:
804 <https://doi.org/10.1128/IAI.01106-13>, PMID: 24478067.
- 805 **Ma X**, Xu TT, Qian MQ, Zhang YC, Yang ZR, Han XY. 2021. Faecal microbiota transplantation alleviates
806 early-life antibiotic-induced gut microbiota dysbiosis and mucosa injuries in a neonatal piglet model.
807 *Microbiological Research* **255**:126942. DOI: <https://doi.org/10.1016/j.micres.2021.126942>, PMID:
808 34915267.
- 809 **Nash TJ**, Morris KM, Mabbott NA, Vervelde L. 2021. Inside-out chicken enteroids with leukocyte
810 component as a model to study host-pathogen interactions. *Communications Biology* **4**(1):377. DOI:
811 <https://doi.org/10.1038/s42003-021-01901-z>, PMID: 33742093.
- 812 **Nguyen LH**, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song MY, Joshi AD, Staller K, Chan AT,
813 Khalili H, Olén O, Ludvigsson JF. 2020. Antibiotic use and the development of inflammatory bowel
814 disease: a national case-control study in Sweden. *Lancet Gastroenterology & Hepatology* **5**(11):986-995.
815 DOI: [https://doi.org/10.1016/S2468-1253\(20\)30267-3](https://doi.org/10.1016/S2468-1253(20)30267-3), PMID: 32818437.
- 816 **Niehrs C**. 2012. The complex world of WNT receptor signaling. *Nature Reviews Molecular Cell Biology*
817 **13**(12):767-779. DOI: <https://doi.org/10.1038/nrm3470>, PMID: 23151663.
- 818 **Ottman N**, Reunanen J, Meijerink M, Pietilä TE, Kainulainen V, Klievink J, Huuskonen L, Aalvink S,
819 Skurnik M, Boeren S, Satokari R, Mercenier A, Palva A, Smidt H, de Vos WM, Belzer C. 2017. Pili-like
820 proteins of *Akkermansia muciniphila* modulate host immune responses and gut barrier function. *PLoS*
821 *One* **12**(3):e0173004. DOI: <https://doi.org/10.1371/journal.pone.0173004>, PMID: 28249045.
- 822 **Plovier H**, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T,
823 Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KCH, Aalvink S,
824 Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani
825 PD. 2017. A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium
826 improves metabolism in obese and diabetic mice. *Nature Medicine* **23**(1):107-113. DOI:
827 <https://doi.org/10.1038/nm.4236>, PMID: 27892954.
- 828 **Quraishi MN**, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. 2017. Systematic review with
829 meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and
830 refractory *Clostridium difficile* infection. *Alimentary Pharmacology & Therapeutics* **46**(5):479-493. DOI:
831 <https://doi.org/10.1111/apt.14201>, PMID: 28707337.
- 832 **Ring A**, Kim YM, Kahn M. 2014. Wnt/Catenin Signaling in Adult Stem Cell Physiology and Disease. *Stem*
833 *Cell Reviews and Reports* **10**(4):512-525. DOI: <https://doi.org/10.1007/s12015-014-9515-2>, PMID:
834 24825509.

- 835 **Sato T**, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P,
836 Peters PJ, Clevers H. 2009. Single Lgr5 stem cells build crypt-villus structures *in vitro* without a
837 mesenchymal niche. *Nature* **459**(7244):262-U147. DOI: <https://doi.org/10.1038/nature07935>, PMID:
838 19329995.
- 839 **Shi Y**, Shu B, Yang RH, Xu YB, Xing BR, Liu J, Chen L, Qi SH, Liu XS, Wang P, Tang JM, Xie JL. 2015.
840 Wnt and Notch signaling pathway involved in wound healing by targeting *c-Myc* and *Hes1* separately.
841 *Stem Cell Research & Therapy* **6**:120. DOI: <https://doi.org/10.1186/s13287-015-0103-4>, PMID:
842 26076648/
- 843 **Smith D**, Price DRG, Burrells A, Faber MN, Hildersley KA, Chintoan-Uta C, Chapuis AF, Stevens M,
844 Stevenson K, Burgess STG, Innes EA, Nisbet AJ, McNeilly TN. 2021. The Development of Ovine
845 Gastric and Intestinal Organoids for Studying Ruminant Host-Pathogen Interactions. *Frontiers in*
846 *Cellular and Infection Microbiology* **11**:733811. DOI: <https://doi.org/10.3389/fcimb.2021.733811>, PMID:
847 34568096.
- 848 **Sprangers J**, Zaalberg IC, Maurice MM. 2021. Organoid-based modeling of intestinal development,
849 regeneration, and repair. *Cell Death and Differentiation* **28**(1):95-107. DOI:
850 <https://doi.org/10.1038/s41418-020-00665-z>, PMID: 33208888.
- 851 **Sun FT**, Zhang QS, Zhao JX, Zhang H, Zhai QX, Chen W. 2019. A potential species of next-generation
852 probiotics? The dark and light sides of *Bacteroides fragilis* in health. *Food Research International*
853 **126**:108590. DOI: <https://doi.org/10.1016/j.foodres.2019.108590>, PMID: 31732047.
- 854 **Sun YW**, Kim SW. 2017. Intestinal challenge with enterotoxigenic *Escherichia coli* in pigs, and nutritional
855 intervention to prevent postweaning diarrhea. *Animal Nutrition* **3**(4):322-330. DOI:
856 <https://doi.org/10.1016/j.aninu.2017.10.001>, PMID: 29767133.
- 857 **Troy EB**, Kasper DL. 2010. Beneficial effects of *Bacteroides fragilis* polysaccharides on the immune
858 system. *Frontiers in Bioscience-Landmark* **15**:25-34. DOI: <https://doi.org/10.2741/3603>, PMID:
859 20036803.
- 860 **Wang C**, Li SJ, Hong K, Yu LL, Tian FW, Zhao JX, Zhang H, Chen W, Zhai QX. 2021. The roles of
861 different *Bacteroides fragilis* strains in protecting against DSS-induced ulcerative colitis and related
862 functional genes. *Food & Function* **12**(18):8300-8313. DOI: <https://doi.org/10.1039/d1fo00875g>, PMID:
863 34308455.
- 864 **Wang WW**, Wang Y, Hao XR, Duan YX, Meng ZQ, An XP, Qi JW. 2020. Dietary fermented soybean meal
865 replacement alleviates diarrhea in weaned piglets challenged with enterotoxigenic *Escherichia coli* K88
866 by modulating inflammatory cytokine levels and cecal microbiota composition. *BMC Veterinary*
867 *Research* **16**(1):245. DOI: <https://doi.org/10.1186/s12917-020-02466-5>, PMID: 32664940.
- 868 **Witkowski M**, Weeks TL, Hazen SL. 2020. Gut Microbiota and Cardiovascular Disease. *Circulation*
869 *Research* **127**(4):553-570. DOI: <https://doi.org/10.1161/CIRCRESAHA.120.316242>, PMID: 32762536.
- 870 **Wlodarska M**, Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N, Russell SL, Vallance BA,
871 Finlay BB. 2011. *Infection and Immunity* **79**(4):1536-1545. DOI: <https://doi.org/10.1128/IAI.01104-10>,
872 PMID: 21321077.
- 873 **Xie WC**, Song LY, Wang XY, Xu YG, Liu ZS, Zhao DF, Wang SB, Fan XL, Wang ZR, Gao C, Wang XN,
874 Wang L, Qiao XY, Zhou H, Cui W, Jiang YP, Li YJ, Tang LJ. 2021. A bovine lactoferricin-
875 lactoferrampin-encoding *Lactobacillus reuteri* CO21 regulates the intestinal mucosal immunity and
876 enhances the protection of piglets against enterotoxigenic *Escherichia coli* K88 challenge. *Gut Microbes*
877 **13**(1):1956281. DOI: <https://doi.org/10.1080/19490976.2021.1956281>, PMID: 34369287.

- 878 **Yan KS**, Janda CY, Chang JL, Zheng GXY, Larkin KA, Luca VC, Chia LA, Mah AT, Han A, Terry JM,
879 Ootani A, Roelf K, Lee M, Yuan J, Li X, Bolen CR, Wilhelmy J, Davies PS, Ueno H, von Furstenberg RJ,
880 Belgrader P, Ziraldo SB, Ordonez H, Henning SJ, Wong MH, Snyder MP, Weissman IL, Hsueh AJ,
881 Mikkelsen TS, Garcia KC, Kuo CJ. 2017. Non-equivalence of Wnt and R-spondin ligands during Lgr5⁺
882 intestinal stem-cell self-renewal. *Nature* **545**(7653):238-242. DOI: <https://doi.org/10.1038/nature22313>,
883 PMID: 28467820.
- 884 **Yin YB**, Guo SG, Wan D, Wu X, Yin YL. 2019. Enteroids: Promising in Vitro Models for Studies of
885 Intestinal Physiology and Nutrition in Farm Animals. *Journal of Agricultural and Food Chemistry*
886 **67**(9):2421-2428. DOI: <https://doi.org/10.1021/acs.jafc.8b06908>, PMID: 30739438.
- 887 **Yu HT**, Ding XL, Shang LJ, Zeng XF, Liu HB, Li N, Huang S, Wang YM, Wang G, Cai S, Chen MX,
888 Levesque CL, Johnston LJ, Qiao SY. 2018. Protective Ability of Biogenic Antimicrobial Peptide
889 Microcin J25 Against Enterotoxigenic Escherichia Coli-Induced Intestinal Epithelial Dysfunction and
890 Inflammatory Responses IPEC-J2 Cells. *Frontiers in Cellular and Infection Microbiology* **8**:242. DOI:
891 <https://doi.org/10.3389/fcimb.2018.00242>, PMID: 30057893.
- 892 **Zhai R**, Xue XH, Zhang LY, Yang X, Zhao LP, Zhang CH. 2019. Strain-Specific Anti-inflammatory
893 Properties of Two *Akkermansia muciniphila* Strains on Chronic Colitis in Mice. *Frontiers in Cellular*
894 *and Infection Microbiology* **9**:239. DOI: <https://doi.org/10.3389/fcimb.2019.00239>, PMID: 31334133.
- 895 **Zhang L**, Qin QQ, Liu MN, Zhang XL, He F, Wang GQ. 2018. *Akkermansia muciniphila* can reduce the
896 damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in
897 streptozotocin-induced diabetic rats. *Pathogens and Disease* **76**(4):fty028. DOI:
898 <https://doi.org/10.1093/femspd/fty028>, PMID: 29668928.
- 899 **Zheng SY**, Li HX, Xu RC, Miao WT, Dai MY, Ding ST, Liu HD. 2021. Potential roles of gut microbiota
900 and microbial metabolites in Parkinson's disease. *Ageing Research Reviews* **69**:101347. DOI:
901 <https://doi.org/10.1016/j.arr.2021.101347>, PMID: 33905953.
- 902 **Zheng Y**, Wang L, Zhang JP, Yang JY, Zhao ZM, Zhang XY. 2010. Expression of p53, c-erbB-2 and Ki67
903 in intestinal metaplasia and gastric carcinoma. *World Journal of Gastroenterology* **16**(3):339-344. DOI:
904 <https://doi.org/10.3748/wjg.v16.i3.339>, PMID: 20082479.
- 905 **Zhou JY**, Huang DG, Gao CQ, Yan HC, Zou SG, Wang XQ. 2021. Heat-stable enterotoxin inhibits
906 intestinal stem cell expansion to disrupt the intestinal integrity by downregulating the Wnt/ β -catenin
907 pathway. *Stem Cell* **39**(4):482-496. DOI: <https://doi.org/10.1002/stem.3324>, PMID: 33373490.
- 908 **Zhu LD**, Lu XX, Liu L, Voglmeir J, Zhong X, Yu QH. 2020. *Akkermansia muciniphila* protects intestinal
909 mucosa from damage caused by *S. pullorum* by initiating proliferation of intestinal epithelium.
910 *Veterinary Research* **51**(1):34. DOI: <https://doi.org/10.1186/s13567-020-00755-3>, PMID: 32138776.
911
912

913 **Figure legends:**

914 **Figure 1. Experimental designs of the present study.** (A) Schematic diagram of the FMT administered to
915 the AIMD piglets infected with ETEC K88. (B) Schematic diagram of the alleviatory effects of *A.*
916 *muciniphila* and *B. fragilis* on ETEC K88 infection in mice. (C) Schematic diagram of the alleviatory
917 effects of *A. muciniphila* on ETEC K88 infection in porcine basal-out and apical-out intestinal organoids.

918 **Figure 2. FMT improved the growth performance and inflammatory response of AIMD piglets**
919 **infected with ETEC K88.** (A) Average daily weight gain (ADG) in the Con, EP and EF groups. (B)
920 Diarrhea score at days 3 and 6 post-infection. (C) The colonization of ETEC K88 in the jejunum and colon.
921 The melting curve demonstrated that only the ETEC K88 could be amplified by the primers we used. (D)
922 The relative mRNA expression of cytokines in the jejunum. Con: control group, EP: ETEC K88 + PBS
923 group, EF: ETEC K88 + FMT group. Data are expressed as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***,
924 $P < 0.001$.

925 **Figure 3. FMT improved the intestinal morphology and barrier function in AIMD piglets infected**
926 **with ETEC K88.** (A) SEM images of villi (top) and microvilli (bottom) in the jejunum (scale bars = 300 or
927 2 μ m). (B) The relative mRNA expression of tight junction proteins (ZO-1, claudin and occludin) and
928 adheren junctions (β -catenin and E-cadherin) in the jejunum. (C) The relative protein expression of tight
929 junction proteins (ZO-1, claudin and occludin) and adheren junction proteins (β -catenin and E-cadherin)
930 in the jejunum. (D) Immunofluorescence images of Mucin 2 (MUC2, green) in the jejunum (scale bars = 50
931 μ m). Con: control group, EP: ETEC K88 + PBS group, EF: ETEC K88 + FMT group. Data are expressed
932 as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$. Data shown are representative of at least two independent
933 experiments.

934 **Figure 4. FMT changed the composition of gut microbiota and the concentration of SCFAs in AIMD**
935 **piglets infected with ETEC K88.** (A) Anosim analysis. (B) UPGMA clustering analysis based on
936 Unweighted unifracc distance. (C) LEfSe analysis with LDA score > 4 . (D) Quantification of SCFA
937 metabolites (acetic acid, propionic acid, butyric acid, isobutyric acid, isovaleric acid and hexanoic acid). EP:
938 ETEC K88 + PBS group, EF: ETEC K88 + FMT group. Data are expressed as the mean \pm SD. *, $P < 0.05$,
939 **, $P < 0.01$. Data shown are representative of at least two independent experiments.

940 **Figure 5. *A. muciniphila* and *B. fragilis* improved the intestinal morphology of mice infected with**
941 **ETEC K88.** (A) H&E-stained images of jejunum (scale bars = 50 μ m) and the histograms of villus height,
942 crypt depth and the ratio of villus height to crypt depth. (B) TEM images of jejunum and colon (scale bars
943 = 0.5 μ m). (C) Immunofluorescence images of Mucin 2 (MUC2, green) in the jejunum and colon (scale
944 bars = 50 μ m). C: control group, E: ETEC K88 + PBS group, A: ETEC K88 + *A. muciniphila* group, B:
945 ETEC K88 + *B. fragilis* group. Data are expressed as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***, $P <$
946 0.001. Data shown are representative of at least two independent experiments.

947 **Figure 6. *A. muciniphila* and *B. fragilis* regulated the expression of inflammatory cytokines and the**
948 **balance of Treg and Th17 cells in mice infected with ETEC K88.** (A) The relative mRNA expression of
949 cytokines in the jejunum. (B) Flow cytometric dot plots and proportions of Treg (CD25⁺Foxp3⁺), Th17
950 (CD4⁺ROR γ t⁺) and mature dendritic cells (CD86⁺CD11C⁺) in jejunal lamina propria. C: control group, E:
951 ETEC K88 + PBS group, A: ETEC K88 + *A. muciniphila* group, B: ETEC K88 + *B. fragilis* group. Data
952 are expressed as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. Data shown are representative of
953 at least two independent experiments.

954 **Figure 7. *A. muciniphila* and *B. fragilis* enhanced the number of Ki67 cells and Lyz Paneth cells in**
955 **jejunal crypt of mice infected with ETEC K88 by moderately activating the Wnt/ β -catenin pathway.**






956 (A) The mRNA expression and immunofluorescence staining images of intestinal epithelial cell
957 proliferation marker Ki67 (red). (B) The mRNA expression and immunofluorescence staining images of
958 Paneth marker Lyz (green). (C) The relative mRNA expression of *Lgr5*, *Wnt3*, *Notch1* and other genes in
959 jejunum mucosa. (D) The relative protein expression of Wnt/ β -catenin pathway and its target genes in
960 jejunum mucosa. C: control group, E: ETEC K88 + PBS group, A: ETEC K88 + *A. muciniphila* group, B:
961 ETEC K88 + *B. fragilis* group. Data are expressed as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***, $P <$
962 0.001. Data shown are representative of at least two independent experiments.













963 **Figure 8. *A. muciniphila* and *B. fragilis* promoted the activity of $Lgr5^+$ intestinal stem cells as proved**
964 **by the growth of intestinal organoids.** (A) Morphology of *ex vivo* culture of crypts isolated from the
965 jejunum of mice in the C, E, A and B groups (Day 5; 4 \times , scale bars = 200 μ m; 20 \times , scale bars = 50 μ m).
966 (B) The surface area and forming efficiency of intestinal organoids. (C) The relative mRNA expression of
967 genes related to the proliferation and differentiation of the intestinal organoids. C: control group, E: ETEC
968 K88 + PBS group, A: ETEC K88 + *A. muciniphila* group, B: ETEC K88 + *B. fragilis* group. Data are
969 expressed as the mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. Data shown are representative of at
970 least two independent experiments.

971 **Figure 9. *A. muciniphila* protected the $Lgr5^+$ intestinal stem cell and activated the Wnt/ β -catenin**
972 **signaling pathway of the ETEC K88-induced basal-out intestinal organoids.** (A) The relative mRNA
973 expression of *villin*, *ZO-1*, *Ki67*, *Lyz1*, *MUC2*, *Lgr5*, *Wnt3a* and *β -catenin* genes. (B)-(F)
974 Immunofluorescence images of villin (scale bars = 50 μ m), Ki67 (scale bars = 50 μ m), *Lgr5* (scale bars =
975 20 μ m), *Wnt3a* (scale bars = 50 μ m) and *β -catenin* (scale bars = 50 μ m). (G) Fold change of the mean
976 fluorescence intensity. CON: control group, ETEC: ETEC K88 + DMEM/F-12 group, AKK: ETEC K88 +
977 *A. muciniphila* group, WNT-C59: Wnt-C59 + ETEC K88 + *A. muciniphila* group. Data are expressed as the
978 mean \pm SD. *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. Data shown are representative of at least two
979 independent experiments.


980 **Figure 10. *A. muciniphila* alleviated the intestinal epithelial injury of the ETEC K88-induced apical-**
981 **out intestinal organoids.** (A) Confocal microscope visualization of the apical-out intestinal organoids
982 incubated in FD4 solution (scale bars = 50 μ m). (B) The relative mRNA expression of *villin*, *ZO-1*, *Ki67*,
983 *Lyz1*, *MUC2*, *Lgr5*, *Wnt3a* and *β -catenin* genes. (C)-(G) Immunofluorescence images of villin, Ki67, *Lgr5*,
984 *Wnt3a* and *β -catenin* (scale bars = 20 μ m). (H) Quantification of the apical-out intestinal organoids
985 incubated in FD4 solution that have intact barrier integrity. (I) Fold change of the mean fluorescence
986 intensity. (J) The relative mRNA expression of cytokines in the apical-out intestinal organoids. CON:
987 control group, ETEC: ETEC K88 + DMEM/F-12 group, AKK: ETEC K88 + *A. muciniphila* group, WNT-
988 C59: Wnt-C59 + ETEC K88 + *A. muciniphila* group. Data are expressed as the mean \pm SD. *, $P < 0.05$, **,
989 $P < 0.01$, ***, $P < 0.001$. Data shown are representative of at least two independent experiments.

990








A




B










C










D














A




A







B




C



D



B



C

